Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 5/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.49 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21851632 | 0.87 | CHRNA1 (0.58) | KCNH2CHRNA1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22522388 | 0.86 | KCNH2 (0.51) | KCNH2CHRNA1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1793080 | 0.83 | KCNH2 (0.62) | KCNH2CHRNA1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL21851605 | 0.83 | CHRNA1 (0.49) | KCNH2CHRNA1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL21851607 | 0.82 | KCNH2 (0.47) | KCNH2CHRNA1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL21851709 | 0.81 | KCNH2 (0.50) | KCNH2CHRNA1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22522390 | 0.76 | KCNH2 (0.50) | KCNH2CHRNA1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22522555 | 0.76 | CHRNA1 (0.65) | KCNH2CHRNA1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL21851634 | 0.76 | CHRNA1 (0.65) | KCNH2CHRNA1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22522653 | 0.76 | KCNH2 (0.50) | KCNH2CHRNA1CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147243-A1 | LIGAND COMPOUND OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AND APPLICATION THEREOF | BEIJING NORMAL UNIVERSITY (CN) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147243-A1 | LIGAND COMPOUND OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AND APPLICATION THEREOF | CHRNA7, CHRNG, CHRNE | KCNH2 269/4885CHRNA1 4/4885CHRNB2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.